Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Inventiva
  6. News
  7. Summary
    IVA   FR0013233012

INVENTIVA

(IVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inventiva : AbbVie to Initiate Phase 2B Study of Autoimmune Disease Drug

05/13/2021 | 04:39am EDT


© MT Newswires 2021
All news about INVENTIVA
07/28INVENTIVA : Reports First-Half of 2021 Financial Information
GL
07/28Inventiva S.A. Reports Revenue Results for the First Half of 2021
CI
07/22INVENTIVA : Half-yearly review of the liquidity contract with Kepler Cheuvreux
PU
07/22INVENTIVA : Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuv..
GL
07/20INVENTIVA : Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuv..
PU
07/02INVENTIVA : Corporate Presentation July 2021
PU
06/15INVENTIVA TO PARTICIPATE AT THE SVB : Liver Disease Day
GL
06/09Inventiva announces three scientific presentations at the EASL International ..
GL
05/25INVENTIVA : to participate at the Jefferies Virtual Healthcare Conference
GL
05/14INVENTIVA : reports first quarter 2021 financial information and updates on the ..
PU
More news
Financials
Sales 2021 3,42 M 4,06 M 4,06 M
Net income 2021 -51,4 M -61,0 M -61,0 M
Net cash 2021 72,0 M 85,5 M 85,5 M
P/E ratio 2021 -8,46x
Yield 2021 -
Capitalization 443 M 525 M 526 M
EV / Sales 2021 109x
EV / Sales 2022 255x
Nbr of Employees 91
Free-Float 72,7%
Chart INVENTIVA
Duration : Period :
Inventiva Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVENTIVA
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 11,46 €
Average target price 26,59 €
Spread / Average Target 132%
EPS Revisions
Managers and Directors
Frédéric Cren Chairman & Chief Executive Officer
Jean Volatier Chief Financial & Administrative Officer
Pierre Broqua Director, Deputy CEO & Chief Scientific Officer
Michael P. Cooreman Chief Medical Officer
Chris Buyse Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INVENTIVA-2.22%525
GILEAD SCIENCES, INC.19.86%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.33.61%68 112
REGENERON PHARMACEUTICALS20.70%59 505
VERTEX PHARMACEUTICALS-14.71%52 232